Retatrutide
Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Pricing for Retatrutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Retatrutide
256 third-party tests across 37 vendors. Each card links to the full report.
For
Retatrutide
by Prime Peptides· batch 4032026RT
For
Retatrutide
by Prime Peptides· batch 3302026RT
For
Retatrutide
by Ion Peptide· batch IONR10-05042026
For
Retatrutide
by Ion Peptide· batch ION3R30-05042026
For
Retatrutide
by Skye Peptides· batch RET26-12-004
For
Retatrutide
by Skye Peptides· batch RET26-24-003
For
Retatrutide
by Skye Peptides· batch RET26-12-003
For
Retatrutide
by Prime Peptides· batch 3202026RT
For
Retatrutide
by Prime Peptides· batch 3172026RT
For
Retatrutide
by Reta Peptide· batch 20260409
For
Retatrutide
by NG Peptide· batch RT10-0429
For
Retatrutide
by MJT peptides· batch cmojgqr2x00089grxxqeujfbs
For
Retatrutide
by Skye Peptides· batch RET26-12-002
For
Retatrutide
by Hkuppeptide· batch 2026
For
Retatrutide
by Peptiatlas· batch 2026
For
Retatrutide
by Taikangbio· batch 2026
For
Retatrutide
by Taishijie· batch 2026
For
Retatrutide
by Vicopeptide· batch 2026
For
Retatrutide
by Zjpeptix· batch 2026
For
Retatrutide
by Peptidegurus· batch cmojgr961002x9grxpliok88f
For
Retatrutide
by Peptidegurus· batch cmojgr3th00249grxwp4haq8g
For
Retatrutide
by OROS Research· batch OR-LPGLPR10-326-B2
For
Retatrutide
by Blank Peptides· batch 665394
For
Retatrutide
by Crush Research· batch CR-3XAG14-2604-1
33 citations indexed for Retatrutide
Study · 2026
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide
Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).
Study · 2026
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
Study · 2026
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.
Study · 2026
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Background and hypothesis Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D).
animal · 2026
Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models
Objective/methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
meta-analysis · 2026
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Introduction Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects.